Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | PHASE1 | RECRUITING | 42 | — | — | Mar 11, 2025 | Jul 1, 2032 | Dec 3, 2025 | 4 | United States, Australia |
The frequency and severity of treatment emergent adverse events and serious adverse events will be assessed when IOV-3001 administered
Determine the recommended dose for Phase 2
| Arm | Type | Description |
|---|---|---|
| Assigned Interventions | EXPERIMENTAL | Dose escalation participants with unresectable or metastatic melanoma |
| Name | Type | Description |
|---|---|---|
| IOV-3001 | BIOLOGICAL | IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting. |
Inclusion Criteria: 1. Participant must be ≥ 18 years of age at the time of signing the informed consent. 2. Participant has unresectable or metastatic melanoma. 3. Participant has melanoma not of uveal/ocular origin and experienced documented radiographic disease progression during systemic therap...